Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2025-08-01 Declaration of Voting R…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a regulatory announcement from AstraZeneca PLC regarding its total voting rights and issued share capital, filed in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of disclosure is a standard regulatory requirement for listed companies to inform shareholders of the denominator for transparency calculations. As it is a general regulatory announcement that does not fit into specific categories like 'Major Shareholding Notification' (which concerns individual investors) or 'Share Issue' (which concerns specific capital changes), it falls under the 'Regulatory Filings' (RNS) category.
2025-08-01 English
FORM 6-K
Regulatory Filings
2025-07-29 English
H1 and Q2 2025 results
Earnings Release Classification · 100% confidence The document is an official announcement from AstraZeneca PLC regarding its H1 and Q2 2025 financial results. It contains detailed revenue summaries, EPS data, pipeline updates, and guidance. While it is a comprehensive summary of financial performance, it is structured as an 'Earnings Release' (ER) issued via RNS (Regulatory News Service), providing key highlights rather than the full, audited interim financial report itself. It follows the standard format for quarterly earnings announcements. H1 2025
2025-07-29 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive H1 and Q2 2025 financial report for AstraZeneca. It includes detailed financial statements, revenue summaries, core EPS, interim dividend information, and a responsibility statement from the directors. It is not merely an announcement or a short summary, but the full interim financial report itself, which fits the definition of an Interim / Quarterly Report (IR). H1 2025
2025-07-29 English
GEFURULIMAB NANOBODY MET PHASE III ENDPOINTS
Regulatory Filings
2025-07-24 English
Gefurulimab nanobody met Phase III endpoints
Regulatory Filings Classification · 98% confidence The document is a press release issued via the Regulatory News Service (RNS) regarding positive clinical trial results for a pharmaceutical product (gefurulimab). It does not constitute a formal financial report, earnings release, or investor presentation, but rather a corporate announcement of scientific progress. As it is a general regulatory announcement that does not fit into more specific categories like earnings or M&A, it is classified as a Regulatory Filing (RNS).
2025-07-24 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.